Posts by: Jose Marques Lopes, PhD

New therapies to treat sickle cell disease (SCD) may receive a boost after CSL Behring‘s recent $91 million acquisition of Calimmune. CSL Behring will now develop Calimmune’s pre-clinical product, CAL-H — ... Read more

June 6, 2017June 6, 2017

New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial Shows

A new pre-transplant conditioning regimen remarkably improves rejection rates and survival in children with sickle cell disease (SCD), according to the results of Phase 1/2 trial (NCT00920972). The study, ... Read more

May 18, 2017May 18, 2017

New Method of Creating Healthy Stem Cells Could Potentially Improve Treatment of Sickle Cell Anemia

Researchers at New York’s Weill Cornell Medicine have discovered an innovative method of producing healthy stem cells that could significantly improve treatment of sickle cell anemia and other blood disorders. ... Read more

May 9, 2017May 9, 2017

Sickle Cell Disease and Its Toll Compared in Different Age Groups in Study

Differences in comorbidities, pain, healthcare utilization and psychosocial outcomes were addressed in three groups of sickle cell disease (SCD) patients, distinguished by their respective ages, in the Pain in ... Read more

March 14, 2017

Sickle Cell Trait Linked with Greater Risk of Developing End-Stage Kidney Disease, Study Shows

Individuals with sickle cell trait (SCT), a common hemoglobin gene variant in African-Americans, have an increased risk of developing kidney disease, new research shows. These findings may have important implications ... Read more